Patents by Inventor John R Medich

John R Medich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS
    Publication number: 20180110854
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: June 5, 2017
    Publication date: April 26, 2018
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • USES AND COMPOSITIONS FOR TREATMENT OF PSORIATIC ARTHRITIS
    Publication number: 20170210795
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Application
    Filed: April 13, 2017
    Publication date: July 27, 2017
    Inventors: John R. Medich, Robert L. Wong, Renee J. Perdok, Eric H. Sasso, Rebecca S. Hoffman, Philip Mease, Christopher T. Ritchlin
  • Methods for treating juvenile idiopathic arthritis
    Patent number: 9669093
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 6, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Uses and compositions for treatment of psoriatic arthritis
    Patent number: 9624295
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: April 18, 2017
    Assignee: Abbvie Biotechnology Ltd.
    Inventors: John R. Medich, Robert L. Wong, Renee J. Perdok, Eric H. Sasso, Rebecca S. Hoffman, Phillip Mease, Christopher T. Ritchlin
  • Uses and Compositions for Treatment of Juvenile Rheumatoid Arthritis
    Publication number: 20160280776
    Abstract: The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of JRA in a subject.
    Type: Application
    Filed: November 9, 2015
    Publication date: September 29, 2016
    Inventors: John R. Medich, Nicolino Ruperto, Alberto Martini, Daniel J. Lovell, Edward H. Giannini
  • Methods for Treating Juvenile Idiopathic Arthritis
    Publication number: 20160151488
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 2, 2016
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods for treating juvenile idiopathic arthritis
    Patent number: 9284370
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: March 15, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods for Treating Juvenile Idiopathic Arthritis
    Publication number: 20160060336
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: April 6, 2015
    Publication date: March 3, 2016
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods for treating juvenile idiopathic arthritis by inhibition of TNF?
    Patent number: 8999337
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: April 7, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Method of treating ankylosing spondylitis
    Patent number: 8926975
    Abstract: The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of ankylosing spondylitis in a subject.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: January 6, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Robert L. Wong, Hartmut Kupper, John R. Medich
  • USES AND COMPOSITIONS FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20120171123
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: October 25, 2011
    Publication date: July 5, 2012
    Inventors: John R. Medich, Hartmut Kupper, John L. Perez, Jeffrey D. Kent, Eric H. Sasso, Oscar Segurado, George Spencer-Green, Theodore Pincus
  • Methods for treating juvenile idiopathic arthritis
    Publication number: 20090258018
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: June 10, 2008
    Publication date: October 15, 2009
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Uses and compositions for treatment of psoriatic arthritis
    Publication number: 20090028794
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Application
    Filed: April 10, 2007
    Publication date: January 29, 2009
    Inventors: John R. Medich, Robert L. Wong, Renee J. Perdok, Eric H. Sasso, Rebecca S. Hoffman, Phillip Mease, Christopher T. Ritchlin
  • Uses and compositions for treatment of rheumatoid arthritis
    Publication number: 20080131374
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: May 4, 2007
    Publication date: June 5, 2008
    Inventors: John R. Medich, Hartmut Kupper, Jeffrey D. Kent, John L. Perez, Eric H. Sasso, Oscar Segurado, George Spencer-Green, Theodore Pincus
  • Uses and compositions for treatment of juvenile rheumatoid arthritis
    Publication number: 20080118496
    Abstract: The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of JRA in a subject.
    Type: Application
    Filed: June 11, 2007
    Publication date: May 22, 2008
    Inventors: John R. Medich, Nicolino Ruperto, Alberto Martini, Daniel J. Lovell, Edward Giannini
  • Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
    Patent number: 7135489
    Abstract: A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: November 14, 2006
    Assignee: G. D. Searle & Co.
    Inventors: John J Talley, John R Medich, Kathleen T McLaughlin, Henry T Gaud, Edward E Yonan
  • Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-YL] benzenesulfonamide
    Publication number: 20030004200
    Abstract: A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 2, 2003
    Applicant: G.D. Searle & Co.
    Inventors: John J. Talley, John R. Medich, Kathleen T. McLaughlin, Henry T. Gaud, Edward E. Yonan
  • Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
    Patent number: 6441014
    Abstract: A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: August 27, 2002
    Assignee: G.D. Searle & Co.
    Inventors: John J Talley, John R Medich, Kathleen T McLaughlin, Henry T Gaud, Edward E Yonan
  • Crystalline form of 4- [ 5-methyl-3-phenylisoxazol-4-yl ] benzenesulfonamide
    Publication number: 20010003752
    Abstract: A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.
    Type: Application
    Filed: December 19, 2000
    Publication date: June 14, 2001
    Applicant: G.D. Searle & Co.
    Inventors: John J. Talley, John R. Medich, Kathleen T. McLaughlin, Henry T Gaud, Edward E. Yonan
  • Process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-penty noate
    Patent number: 5631399
    Abstract: The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: May 20, 1997
    Assignee: G. D. Searle & Co.
    Inventors: Kevin A. Babiak, Srinivasan Babu, James R. Behling, Mark L. Boys, Kimberly J. Cain-Janicki, Wendel W. Doubleday, Payman Farid, Timothy J. Hagen, E. A. Hallinan, Donald W. Hansen, Jr., Donald E. Korte, Kathleen T. Mc Laughlin, John R. Medich, Sean T. Nugent, Vlasdislav Orlovski, Jung M. Park, Karen B. Peterson, Daniel R. Pilipauskas, Barnett S. Pitzele, Sofya Tsymbalov, Glenn L. Stahl